Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2009-10-12
2011-12-20
Aulakh, Charanjit (Department: 1625)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C546S048000
Reexamination Certificate
active
08080559
ABSTRACT:
A 5(S)-(2′-hydroxyethoxy)-20(S)-camptothecin diasterisomer is described which is a better inhibitor of topoisomerase I than either the diastereoisomeric mixture 5(RS)-(2′-hydroxyethoxy)-20(S)-camptothecin, or the 5(R)-(2′-hydroxyethoxy)-20(S)-camptothecin diastereoisomer. Pharmaceutical compositions of the 5(S)-(2′-hydroxyethoxy)-20(S)-camptothecin diastereoisomer are also described as are methods of using the compound for the inhibition of topoisomerase I and for the treatment of cancer.
REFERENCES:
patent: 6177439 (2001-01-01), Duvvuri et al.
patent: 7601732 (2009-10-01), Akella et al.
patent: 7601733 (2009-10-01), Akella et al.
Benet et al., Appendix II Design and Optimization of Dosage Regimens; Pharmacokinetic Data, Goodman & Goodman's The Pharmacological Basis of Therapeutics, Ninth Edition, pp. 1707-1711 (1996).
Wall et al., Plant Antitumor Agents. I. The Isolation and Structure of Camptothecin, a Novel Alkaloidal Leukemia and Tumor Inhibitor from Camptotheca acuminata, Journal of the American Chemical Society, (1996), pp. 3888-3890, Volune-Issue 88:16, ACS Publications, Washington, DC.
Poynter et al., Coulometric Karl Fischer titration simplifies water content testing, Oil & Gas Journal, (1994), pp. 1-5, vol.-Issue 92:15, Kam Controls Inc., Houston, TX.
Monks, et al., Feasibility of a High-Flux Anticancer Drug Screen Using a Diverse Panel of Cultured Human Tumor Cell Lines, Journal of the National Cancer Institute, (Jun. 5, 1991), pp. 757-766, Volune-Issue 83:11.
Stewart et al., Gefitinib Enhances the Antitumor Activity and Oral Bioavailability of Irinotecan in Mice, Cancer Research, Oct. 15, 2004), pp. 7491-7499, Volune-Issue 64:2.
Gorlick et al., Biology of Childhood Osteogenic Sarcoma and Potential Targets for Therapeutic Development: Meeting Summary, Clinical Cancer Research, (Nov. 15, 2003), pp. 5442-5453, vol. 9.
Alfonso R. Gennaro, Remington: The Science and Practice of Pharmacy, 20th Edition, (Lippincott, Williams and Wilkins), 2000.
John E. Hoover, Remington's Pharmaceutical Sciences, Mack Publishing Co., Easton Pennsylvania, Fifteenth Edition, 1975.
Liberman et al., Pharmaceutical Dosage Forms: Tablets vols. 1-3, Marcel Decker, New York, N. Y., 1980.
Kibbe et al., Handbook of Pharmaceutical Excipients, Third Edition, American Pharmaceutical Association, Washington, D.C., 1999.
Office Action dated Mar. 28, 2008 from the U.S. Patent and Trademark Office.
Response to the Non-Final Office Action dated Mar. 28, 2008.
Office Action dated Nov. 17, 2008 from the U.S. Patent and Trademark Office.
Response to the Non-Final Office Action dated Nov. 17, 2008.
Advisory Action dated Apr. 1, 2009 from the U.S. Patent and Trademark Office.
Response to the Advisory Office Action dated Apr. 1, 2009 and Final Office Action dated Nov. 17, 2009.
Akella Venkateswarlu
Alikunju Shanavas
Duvvuri Subrahmanyam
Mullangi Ramesh
Rajagopal Sriram
Aulakh Charanjit
Dr. Reddy's Laboratories Inc.
Dr. Reddy's Laboratories Limited
Franks Robert A.
Gupta Balaram
LandOfFree
5(S)-(2′-hydroxyethoxy)-20(S)-camptothecin and its... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with 5(S)-(2′-hydroxyethoxy)-20(S)-camptothecin and its..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and 5(S)-(2′-hydroxyethoxy)-20(S)-camptothecin and its... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4315676